Comparison of effects and safety between peginterferon alfa-2a and peginterferon alfa-2b in simepurevir therapy for chronic hepatitis C.

Comparison of effects and safety between peginterferon alfa-2a and peginterferon alfa-2b in simepurevir therapy for chronic hepatitis C. - Comparison of peginterferon alfa-2a versus peginterferon alfa-2b in simepurevir therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013302

Enrollment

200

Registered

2014-03-03

Start date

2014-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis

Interventions

alfa 2a alfa 2b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: over 20 years old and under 75 years old

Exclusion criteria

Exclusion criteria: there is no problem about randomaization

Design outcomes

Primary

Measure	Time frame
SVR ratio	—

Countries

Japan

Contacts

Public ContactKoichi Honda

Oita Hepatitis C Study Gastroenterology

hondak@oita-u.ac.jp097-549-4411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026